Rethinking cancer detection
Research on early cancer detection has been hamstrung by market failure. We’ve got a plan to fix it.
7th October 2020
Web Exclusives
Breaking borders
How society’s changing relationship with health will break down the wall between pharma brands and consumers
2nd October 2020
A helping hand
How artificial intelligence can help pharma companies reach new audiences
23rd September 2020
What does creativity really mean in healthcare?
And why does it matter more than ever following COVID-19?
21st September 2020
Tackling the energy challenge
Three ways to optimise energy consumption in pharma manufacturing
16th September 2020
Reimagining the pharma training experience
How behavioural science can revolutionise training in the pharma industry
9th September 2020
Beware the super spreaders
Identifying and stopping COVID-19 co-infections with broader diagnostics
9th September 2020
Working in Silos
How pharma can move digitalisation from theory to commercial reality
9th September 2020
Making a meaningful difference for patients with IPF
Galapagos' Walid Abi-Saab on partnering with patients to make a meaningful difference in a rare and misunderstood condition
8th September 2020
How Digital Pharma can learn from other regulated industries
Alternative digital solutions for pharma from other regulated industries
27th August 2020
Will brand pharma take advantage of its new opportunity?
The work pharmaceutical brands have done to overcome an inherent scepticism toward them must be nurtured and built on
20th August 2020
What the COVID-19 pandemic means for access to healthcare
Pharmaceutical companies and technology have a critical role to play in closing gaps seen during COVID-19
19th August 2020
COVID-19 therapy and drug interactions
An overview of current treatments and their potential drug interactions
30th July 2020
